Form 4: Co-Diagnostics CEO Reports Routine Stock Transactions Following RSU Vesting

Co-Diagnostics, Inc. CEO Dwight H. Egan reported the acquisition of 163,334 shares of common stock through restricted stock unit vesting and the subsequent sale of 51,697 shares to cover tax obligations.

Summary

• Dwight H. Egan, the Chief Executive Officer and a Director of Co-Diagnostics, Inc. (CODX), reported stock transactions on May 23, 2025, as detailed in a Form 4 filing.
• Mr. Egan acquired 163,334 shares of common stock at a price of $0.00 per share, which resulted from the vesting of restricted stock units (RSUs) under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan.
• Concurrently, he disposed of 51,697 shares of common stock at a price of $0.24 per share.
• This disposition was a mandatory 'sell to cover' transaction, required by the Issuer's equity incentive plans to satisfy tax withholding obligations associated with the RSU vesting, and was not a discretionary trade by Mr. Egan.
• Following these transactions, Mr. Egan's direct beneficial ownership of common stock stands at 634,494 shares, and he beneficially owns 300,833 restricted stock units.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction filing (Form 4) related to executive compensation. It reflects the vesting of previously granted RSUs and a mandatory tax-related sale, which are standard practices and do not inherently indicate positive or negative company performance or outlook. The low sale price of $0.24 is noted but is a consequence of the stock price at the time of vesting, not a direct sentiment indicator of the transaction itself.

Positives

• The vesting of 163,334 restricted stock units indicates the ongoing execution of the company's long-term incentive plan, aligning executive interests with shareholder value.
• The acquisition of shares at a $0.00 price through RSU vesting represents a non-cash compensation benefit to the CEO.

Negatives

• The sale of 51,697 shares, even if for tax purposes, results in a reduction of the CEO's direct shareholding.
• The sale price of $0.24 per share for the tax-related disposition is notably low, which could reflect a depressed stock price at the time of the transaction.

Risks

• The low share price of $0.24 at which the 'sell to cover' transaction occurred may indicate a low valuation for Co-Diagnostics, Inc., which could be a risk factor for current and prospective investors.

Future Outlook

The document primarily reports past transactions related to executive compensation and does not provide explicit forward-looking statements or guidance regarding the company's future performance or strategic outlook, beyond the ongoing vesting schedule of previously granted restricted stock units.

Management Comments

• "The sale of 51,697 shares represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs."
• "This sale is mandated by the Issuer's election, under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person."

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, specifically related to executive compensation. It does not provide information on broader industry trends or competitive landscape. The 'sell to cover' mechanism for tax obligations is a common practice across various industries for equity compensation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a standard practice across many industries, aligning executive incentives with long-term shareholder value.
• The 'sell to cover' mechanism for tax withholding on RSU vesting is also a widely adopted and standard procedure in corporate equity compensation plans, used by companies like Apple, Microsoft, and Google, to manage tax liabilities without requiring executives to use personal funds.
• The specific value of the shares at the time of the 'sell to cover' transaction ($0.24) is company-specific and cannot be directly compared to industry standards without knowing the company's specific performance relative to its peers in the diagnostics industry.

Stakeholder Impact

• Shareholders: The report provides transparency regarding executive compensation and insider holdings, which can influence investor confidence. The 'sell to cover' transaction, while mandatory, slightly reduces the CEO's direct ownership.
• Employees: The vesting of RSUs for the CEO indicates the company's ongoing use of equity incentive plans, which may be relevant to other employees participating in similar plans.

Next Steps

• Continued vesting of remaining restricted stock units for Dwight H. Egan according to the established 6-month installment schedule for awards granted on June 6, 2022, January 17, 2023, May 15, 2023, and April 26, 2024.

Key Dates

Keywords

Co-Diagnostics, CODX, Dwight H. Egan, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Compensation, Sell to Cover, Beneficial Ownership